Abstract:The newly emerged ribonucleic acid (RNA) enveloped human beta-coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection caused the COVID-19 pandemic, severely affects the respiratory system, and may lead to death. Lacking effective diagnostics and therapies made this pandemic challenging to manage since the SARS-CoV-2 transmits via human-to-human, enters via ACE2 and TMPSSR2 receptors, and damages organs rich in host cells, spreads via symptomatic carriers and is prominent in an immune-compromised population. New SARS-CoV-2 informatics (structure, strains, like-cycles, functional sites) motivated bio-pharma experts to investigate novel therapeutic agents that act to recognize, inhibit, and knockdown combinations of drugs, vaccines, and antibodies, have been optimized to manage COVID-19. However, successful targeted delivery of these agents to avoid off-targeting and unnecessary drug ingestion is very challenging. To overcome these obstacles, this mini-review projects nanomedicine technology, a pharmacologically relevant cargo of size within 10 to 200 nm, for site-specific delivery of a therapeutic agent to recognize and eradicate the SARS-CoV-2, and improving the human immune system. Such combinational therapy based on compartmentalization controls the delivery and releases of a drug optimized based on patient genomic profile and medical history. Nanotechnology could help combat COVID-19 via various methods such as avoiding viral contamination and spraying by developing personal protective equipment (PPE) to increase the protection of healthcare workers and produce effective antiviral disinfectants surface coatings capable of inactivating and preventing the virus from spreading. To quickly recognize the infection or immunological response, design highly accurate and sensitive nano-based sensors. Development of new drugs with improved activity, reduced toxicity, and sustained release to the lungs, as well as tissue targets; and development of nano-based immunizations to improve humoral and cellular immune responses. The desired and controlled features of suggested personalized therapeutics, nanomedicine, is a potential therapy to manage COVID-19 successfully. The state-of-the-art nanomedicine, challenges, and prospects of nanomedicine are carefully and critically discussed in this report, which may serve as a key platform for scholars to investigate the role of nanomedicine for higher efficacy to manage the COVID-19 pandemic.

Nanotechnology‐Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID‐19 Vaccines (Small Methods 9/2021)

Detection, Prevention and Treatment of COVID-19 and Opportunities for Nanobiotechnology.

RNA nanotechnology: a new chapter in targeted therapy

RNA-based nanomedicines and their clinical applications

Introduction to RNA Vaccines Post COVID-19

RNA Cancer Nanomedicine: Nanotechnology-Mediated RNA Therapy.

RNA Nanomedicine: Delivery Strategies and Applications

Advancing mRNA Therapeutics: The Role and Future of Nanoparticle Delivery Systems

Nucleic Acids as Biotools at the Interface between Chemistry and Nanomedicine in the COVID-19 Era

Nanoparticle Technology for Mrna: Delivery Strategy, Clinical Application and Developmental Landscape

Recent Advances and Prospects in RNA Drug Development

RNA technology and nanocarriers empowering in vivo chimeric antigen receptor therapy

From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines

The nano delivery systems and applications of mRNA

Stimuli‐Responsive Nanotechnology for RNA Delivery

Nanomedicine for the SARS-CoV-2: State-of-the-Art and Future Prospects

Non-viral nanoparticles for RNA interference: Principles of design and practical guidelines

Nanotechnology for COVID-19: Therapeutics and Vaccine Research

The Impact of COVID-19 on RNA Therapeutics: A Surge in Lipid Nanoparticles and Alternative Delivery Systems

Nanodelivery of nucleic acids

Bioinspired Spatiotemporal Management toward RNA Therapies